SAN DIEGO -- (BUSINESS WIRE) -- AntiCancer Inc. has announced the development of new technology of combining fluorescence-guided surgery (FGS) of pancreatic cancer with ultraviolet light radiation to eliminate any residual cancer cells remaining after the surgery in mouse models of human pancreatic cancer. AntiCancer is a world leader in both mouse models of human cancer that represent the patient and the development of technology to make tumors fluorescent, allowing the surgeon to visualize the cancer much better than previously possible. “This is a breakthrough in pancreatic cancer surgery that enables the surgeon to visualize the cancer by making it fluorescent, and thereby allows the cancer to better absorb and become sensitive to ultraviolet light, which eradicates any remaining cancer cells not removed by the surgeon in the area of the tumor. This new technology was developed in mouse models of human pancreatic cancer and its application in the clinic could take place in the near future and should improve patient outcome in this highly lethal disease,” said Charlene M. Cooper, spokesperson of AntiCancer Inc. This new technology is described in the new issue of PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0099977).
AntiCancer Inc., founded in 1984 and based in San Diego, with offices and laboratories in Seoul, Beijing, Nanjing and Osaka, has developed the leading mouse models of cancer, including MetaMouse®, AngioMouse® and StromaMouse®. These models are made imageable with AntiCancer’s OncoBrite® technology using fluorescent proteins and are the models of choice for novel drug discovery for cancer. AntiCancer is the foremost pre-clinical cancer contract research organization. AntiCancer offers for sale the world’s largest collection of fluorescent-protein-expressing cancer cell lines and nude mice. AntiCancer is a pioneer in fluorescence-guided surgery of cancer using its patient-like mouse models. AntiCancer is also developing new cancer drugs based on genetic engineering that target cancer-specific metabolic defects, including recombinant methioninase (rMETase). AntiCancer is also developing tumor-targeting bacteria. The company markets recombinant-enzyme-based diagnostics for cancer and cardiovascular disease. AntiCancer offers the Histoculture Drug Response Assay (HDRA) and patient-derived orthotopic xenografts (PDOXTM) for individualized cancer treatment. AntiCancer pioneered hair follicle gene therapy and is now pioneering the use of pluripotent hair-follicle stem cells, termed hair accessible pluripotent (HAP) stem cells, for regenerative medicine for nerve and spinal cord injury.